de Jong Jonas S S G, Rietveld Kirsten, van Lochem Laura T, Bouma Berto J
Department of Cardiology, Academic Medical Center, Room B2-238, PO Box 22660, 1100 DD Amsterdam, The Netherlands.
Eur J Heart Fail. 2009 Feb;11(2):220-2. doi: 10.1093/eurjhf/hfn034.
The aetiology of peripartum cardiomyopathy (PPCM) is still largely unknown. Recent evidence suggests that the breakdown products from prolactin can induce cardiomyopathy. Prolactin secretion can be reduced with bromocriptine which had beneficial effects in a small study. We present a case of a patient with PPCM who received cabergoline, a strong and long lasting antagonist of prolactin secretion. Following treatment, her prolactin levels dropped swiftly. N-terminal pro-BNP levels, which had remained high up to that point, dropped within 1 day (7006 to 4408 pg/mL). Echocardiographic left ventricular ejection fraction recovered from 26% on day 4 postpartum to 32% and later 47% on days 2 and 5 after cabergoline treatment. To our knowledge, this is the first description of a case of PPCM in which cabergoline was administered.
围产期心肌病（PPCM）的病因在很大程度上仍然未知。最近的证据表明，催乳素的分解产物可诱发心肌病。溴隐亭可降低催乳素分泌，在一项小型研究中显示出有益效果。我们报告一例PPCM患者，该患者接受了卡麦角林，一种强效且长效的催乳素分泌拮抗剂。治疗后，她的催乳素水平迅速下降。此前一直居高不下的N末端脑钠肽前体水平在1天内从7006 pg/mL降至4408 pg/mL。超声心动图显示左心室射血分数从产后第4天的26%恢复到卡麦角林治疗后第2天的32%，并在第5天进一步升至47%。据我们所知，这是首例使用卡麦角林治疗PPCM的病例描述。
